Publications of Dr. Emiel van der Vorst over the last 5 years:

  1. Tullemans BME, Fernandez DI, Veninga A, Baaten C, Peters LJF, Aarts MJB, Eble JA, Campello E, Spiezia L, Simioni P, van der Vorst EPC, van der Meijden PEJ, Heemskerk JWM and Kuijpers MJE. Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin. Thromb Haemost. 2022;122:92-104.
     
  2. Soppert J, Frisch J, Wirth J, Hemmers C, Boor P, Kramann R, Vondenhoff S, Moellmann J, Lehrke M, Hohl M, van der Vorst EPC, Werner C, Speer T, Maack C, Marx N, Jankowski J, Roma LP and Noels H. A systematic review and meta-analysis of murine models of uremic cardiomyopathy. Kidney Int. 2022;101:256-273.
     
  3. Kahles F, Rau M, Reugels M, Foldenauer AC, Mertens RW, Arrivas MC, Schroder J, Idel P, Moellmann J, van der Vorst EPC, Marx N and Lehrke M. The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury. Cardiovasc Diabetol. 2022;21:18.
     
  4. Haghikia A, Zimmermann F, Schumann P, Jasina A, Roessler J, Schmidt D, Heinze P, Kaisler J, Nageswaran V, Aigner A, Ceglarek U, Cineus R, Hegazy AN, van der Vorst EPC, Doring Y, Strauch CM, Nemet I, Tremaroli V, Dwibedi C, Krankel N, Leistner DM, Heimesaat MM, Bereswill S, Rauch G, Seeland U, Soehnlein O, Muller DN, Gold R, Backhed F, Hazen SL, Haghikia A and Landmesser U. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. Eur Heart J. 2022;43:518-533.

Stand: Mai 2022

  1. Yan Y, Thakur M, van der Vorst EPC, Weber C and Doring Y. Targeting the chemokine network in atherosclerosis. Atherosclerosis. 2021;330:95-106.
     
  2. van der Vorst EPC, Pepe MAA, Peters LJF, Haberbosch M, Jansen Y, Naumann R, Stathopoulos GT, Weber C and Bidzhekov K. Transcriptome signature of miRNA-26b KO mouse model suggests novel targets.BMC Genom Data. 2021;22:23.
     
  3. van der Vorst EPC and Doring Y. Tracing Endothelial CXCR4 May Pave the Way for Localized Lesional Treatment Approaches. Arterioscler Thromb Vasc Biol. 2021;41:837-838.
     
  4. van der Vorst EPC. c-Kit inhibition: From promising cancer therapy to culprit in atherosclerosis. Atherosclerosis. 2021;324:115-116.
     
  5. Tullemans BME, Fernandez DI, Veninga A, Baaten C, Peters LJF, Aarts MJB, Eble JA, Campello E, Spiezia L, Simioni P, van der Vorst EPC, van der Meijden PEJ, Heemskerk JWM and Kuijpers MJE. Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin. Thromb Haemost. 2021.
     
  6. Sundararaman SS and van der Vorst EPC. Calcium-Sensing Receptor (CaSR), Its Impact on Inflammation and the Consequences on Cardiovascular Health. Int J Mol Sci. 2021;22.
     
  7. Sundararaman SS, Peters LJF, Nazir S, Marquez AB, Bouma JE, Bayasgalan S, Doring Y and van der Vorst EPC. PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vitro and In Vivo. Int J Mol Sci. 2021;22.
     
  8. Sundararaman SS, Peters LJF, Jansen Y, Gencer S, Yan Y, Nazir S, Bonnin Marquez A, Kahles F, Lehrke M, Biessen EAL, Jankowski J, Weber C, Doring Y and van der Vorst EPC. Adipocyte calcium sensing receptor is not involved in visceral adipose tissue inflammation or atherosclerosis development in hyperlipidemic Apoe(-/-) mice. Sci Rep. 2021;11:10409.
     
  9. Sundararaman SS, Doring Y and van der Vorst EPC. PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. Biomedicines. 2021;9.
     
  10. Soppert J, Frisch J, Wirth J, Hemmers C, Boor P, Kramann R, Vondenhoff S, Moellmann J, Lehrke M, Hohl M, van der Vorst EPC, Werner C, Speer T, Maack C, Marx N, Jankowski J, Roma LP and Noels H. A systematic review and meta-analysis of murine models of uremic cardiomyopathy. Kidney Int. 2021.
     
  11. Schumacher D, Liehn EA, Singh A, Curaj A, Wijnands E, Lira SA, Tacke F, Jankowski J, Biessen EAL and van der Vorst EPC. CCR6 Deficiency Increases Infarct Size after Murine Acute Myocardial Infarction. Biomedicines. 2021;9.
     
  12. Peters LJF, Jans A, Bartneck M and van der Vorst EPC. Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis. J Clin Med. 2021;10.
     
  13. Orth-Alampour S, Gayrard N, Salem S, Bhargava S, Jankowski V, Jover B, Notarnicola C, Noels H, van der Vorst EPC, Kuppe C, Wolf M, Goettsch C, Theelen W, Bruck H, Fliser D, Loscalzo J, Wu Z, Marx N, Zidek W, Argiles A and Jankowski J. Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation. Basic Res Cardiol. 2021;116:57.
     
  14. Marquez AB, van der Vorst EPC and Maas SL. Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential. J Clin Med. 2021;10.
     
  15. He YY, Xie XM, Zhang HD, Ye J, Gencer S, van der Vorst EPC, Doring Y, Weber C, Pang XB, Jing ZC, Yan Y and Han ZY. Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension. Front Pharmacol. 2021;12:753727.
     
  16. Haghikia A, Zimmermann F, Schumann P, Jasina A, Roessler J, Schmidt D, Heinze P, Kaisler J, Nageswaran V, Aigner A, Ceglarek U, Cineus R, Hegazy AN, van der Vorst EPC, Doring Y, Strauch CM, Nemet I, Tremaroli V, Dwibedi C, Krankel N, Leistner DM, Heimesaat MM, Bereswill S, Rauch G, Seeland U, Soehnlein O, Muller DN, Gold R, Backhed F, Hazen SL, Haghikia A and Landmesser U. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism.Eur Heart J. 2021.
     
  17. Gencer S, Evans BR, van der Vorst EPC, Doring Y and Weber C. Inflammatory Chemokines in Atherosclerosis. Cells. 2021;10.
     
  18. Gencer S, Doring Y, Jansen Y, Bayasgalan S, Schengel O, Muller M, Peters LJF, Weber C and van der Vorst EPC. Adipocyte-Specific ACKR3 Regulates Lipid Levels in Adipose Tissue. Biomedicines. 2021;9.
  1. van der Vorst EPC, Daissormont I, Aslani M, Seijkens T, Wijnands E, Lutgens E, Duchene J, Santovito D, Doring Y, Halvorsen B, Aukrust P, Weber C, Hopken UE and Biessen EAL. Interruption of the CXCL13/CXCR5 Chemokine Axis Enhances Plasma IgM Levels and Attenuates Atherosclerosis Development. Thromb Haemost. 2020;120:344-347.
     
  2. van der Vorst EPC. High-Density Lipoproteins and Apolipoprotein A1. Subcell Biochem. 2020;94:399-420.
     
  3. Tilstam PV, Soppert J, Hemmers C, Harlacher E, Doring Y, van der Vorst EPC, Schulte C, Alampour-Rajabi S, Theelen W, Asare Y, de Winther MPJ, Lawrence T, Bernhagen J, Schober A, Zernecke A, Jankowski J, Weber C and Noels H. Non-activatable mutant of inhibitor of kappa B kinase alpha (IKKalpha) exerts vascular site-specific effects on atherosclerosis in Apoe-deficient mice. Atherosclerosis. 2020;292:23-30.
     
  4. Saar-Kovrov V, Donners M and van der Vorst EPC. Shedding of Klotho: Functional Implications in Chronic Kidney Disease and Associated Vascular Disease. Front Cardiovasc Med. 2020;7:617842.
     
  5. Peters LJF, Floege J, Biessen EAL, Jankowski J and van der Vorst EPC. MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application. Int J Mol Sci. 2020;21.
     
  6. Peters LJF, Biessen EAL, Hohl M, Weber C, van der Vorst EPC and Santovito D. Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease. Front Physiol. 2020;11:793.
     
  7. Nazir S, Jankowski V, Bender G, Zewinger S, Rye KA and van der Vorst EPC. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration! Adv Drug Deliv Rev. 2020;159:94-119.
     
  8. Marquez AB, Nazir S and van der Vorst EPC. High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression? Biomedicines. 2020;8.
     
  9. Kiouptsi K, Pontarollo G, Todorov H, Braun J, Jackel S, Koeck T, Bayer F, Karwot C, Karpi A, Gerber S, Jansen Y, Wild P, Ruf W, Daiber A, Van Der Vorst E, Weber C, Doring Y and Reinhardt C. Germ-free housing conditions do not affect aortic root and aortic arch lesion size of late atherosclerotic low-density lipoprotein receptor-deficient mice. Gut Microbes. 2020;11:1809-1823.
     
  10. Gencer S, Lacy M, Atzler D, van der Vorst EPC, Doring Y and Weber C. Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19. Thromb Haemost. 2020;120:1629-1641.
     
  11. Doring Y, Noels H, van der Vorst E and Weber C. Seeing is repairing: how imaging-based timely interference with CXCR4 could improve repair after myocardial infarction. Eur Heart J. 2020;41:3576-3578.
     
  12. Doring Y, Jansen Y, Cimen I, Aslani M, Gencer S, Peters LJF, Duchene J, Weber C and van der Vorst EPC. B-Cell-Specific CXCR4 Protects Against Atherosclerosis Development and Increases Plasma IgM Levels. Circ Res. 2020;126:787-788.
  1. van der Vorst, E. P. C. & Weber, C. Novel Features of Monocytes and Macrophages in Cardiovascular Biology and Disease. Arterioscler Thromb Vasc Biol 39, e30-e37, doi:10.1161/ATVBAHA.118.312002 (2019).
     
  2. van der Vorst, E. P. C., Peters, L. J. F., Muller, M., Gencer, S., Yan, Y., Weber, C. & Doring, Y. G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis. Front Pharmacol 10, 531, doi:10.3389/fphar.2019.00531 (2019).
     
  3. van der Vorst, E. P. C., Mandl, M., Muller, M., Neideck, C., Jansen, Y., Hristov, M., Gencer, S., Peters, L. J. F., Meiler, S., Feld, M., Geiselhoringer, A. L., de Jong, R. J., Ohnmacht, C., Noels, H., Soehnlein, O., Drechsler, M., Weber, C. & Doring, Y. Hematopoietic ChemR23 (Chemerin Receptor 23) Fuels Atherosclerosis by Sustaining an M1 Macrophage-Phenotype and Guidance of Plasmacytoid Dendritic Cells to Murine Lesions-Brief Report. Arterioscler Thromb Vasc Biol 39, 685-693, doi:10.1161/ATVBAHA.119.312386 (2019).
     
  4. van der Vorst, E. P. C. & Donners, M. ADAM8 in the cardiovascular system: An innocent bystander with clinical use? Atherosclerosis 286, 147-149, doi:10.1016/j.atherosclerosis.2019.04.205 (2019).
     
  5. Van der Vorst, E. P. C. & Biessen, E. A. L. Unwrapped and uNCORked: PPAR-gamma repression in atherosclerosis. Eur Heart J, doi:10.1093/eurheartj/ehz770 (2019).
     
  6. Kiouptsi, K., Jackel, S., Pontarollo, G., Grill, A., Kuijpers, M. J. E., Wilms, E., Weber, C., Sommer, F., Nagy, M., Neideck, C., Jansen, Y., Ascher, S., Formes, H., Karwot, C., Bayer, F., Kollar, B., Subramaniam, S., Molitor, M., Wenzel, P., Rosenstiel, P., Todorov, H., Gerber, S., Walter, U., Jurk, K., Heemskerk, J. W. M., van der Vorst, E. P. C., Doring, Y. & Reinhardt, C. The Microbiota Promotes Arterial Thrombosis in Low-Density Lipoprotein Receptor-Deficient Mice. mBio 10, doi:10.1128/mBio.02298-19 (2019).
     
  7. Gencer, S., van der Vorst, E. P. C., Aslani, M., Weber, C., Doring, Y. & Duchene, J. Atypical Chemokine Receptors in Cardiovascular Disease. Thromb Haemost 119, 534-541, doi:10.1055/s-0038-1676988 (2019).
     
  8. Doring, Y., van der Vorst, E. P. C., Duchene, J., Jansen, Y., Gencer, S., Bidzhekov, K., Atzler, D., Santovito, D., Rader, D. J., Saleheen, D. & Weber, C. CXCL12 Derived From Endothelial Cells Promotes Atherosclerosis to Drive Coronary Artery Disease. Circulation 139, 1338-1340, doi:10.1161/CIRCULATIONAHA.118.037953 (2019).
  1. van der Vorst, E. P. C., Weber, C. & Donners, M. A Disintegrin and Metalloproteases (ADAMs) in Cardiovascular, Metabolic and Inflammatory Diseases: Aspects for Theranostic Approaches. Thromb Haemost 118, 1167-1175, doi:10.1055/s-0038-1660479 (2018).
     
  2. van der Vorst, E. P. C. & Weber, C. Metabolomic profiling of atherosclerotic plaques: towards improved cardiovascular risk stratification. Eur Heart J 39, 2311-2313, doi:10.1093/eurheartj/ehy117 (2018).
     
  3. van der Vorst, E. P. C. & Doring, Y. Resistin keeps its Janus face. Int J Cardiol 272, 47-48, doi:10.1016/j.ijcard.2018.08.071 (2018).
     
  4. van der Vorst, E. P. C., de Jong, R. J. & Donners, M. Message in a Microbottle: Modulation of Vascular Inflammation and Atherosclerosis by Extracellular Vesicles. Front Cardiovasc Med 5, 2, doi:10.3389/fcvm.2018.00002 (2018).
     
  5. Rinne, P., Guillamat-Prats, R., Rami, M., Bindila, L., Ring, L., Lyytikainen, L. P., Raitoharju, E., Oksala, N., Lehtimaki, T., Weber, C., van der Vorst, E. P. C. & Steffens, S. Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation. Arterioscler Thromb Vasc Biol 38, 2562-2575, doi:10.1161/ATVBAHA.118.311185 (2018).
     
  6. Merckelbach, S., van der Vorst, E. P. C., Kallmayer, M., Rischpler, C., Burgkart, R., Doring, Y., de Borst, G. J., Schwaiger, M., Eckstein, H. H., Weber, C. & Pelisek, J. Expression and Cellular Localization of CXCR4 and CXCL12 in Human Carotid Atherosclerotic Plaques. Thromb Haemost 118, 195-206, doi:10.1160/TH17-04-0271 (2018).
     
  7. Doring, Y. & van der Vorst, E. P. C. Gouty Offense in Patients With Obstructive Coronary Artery Disease Despite State-of-the-Art Therapy. J Am Heart Assoc 7, e010322, doi:10.1161/JAHA.118.010322 (2018).
  1. Weber, C., Badimon, L., Mach, F. & van der Vorst, E. P. C. Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future. Thromb Haemost 117, 1258-1264, doi:10.1160/TH16-10-0814 (2017).
     
  2. van der Vorst, E. P. C., Theodorou, K., Wu, Y., Hoeksema, M. A., Goossens, P., Bursill, C. A., Aliyev, T., Huitema, L. F. A., Tas, S. W., Wolfs, I. M. J., Kuijpers, M. J. E., Gijbels, M. J., Schalkwijk, C. G., Koonen, D. P. Y., Abdollahi-Roodsaz, S., McDaniels, K., Wang, C. C., Leitges, M., Lawrence, T., Plat, J., Van Eck, M., Rye, K. A., Touqui, L., de Winther, M. P. J., Biessen, E. A. L. & Donners, M. High-Density Lipoproteins Exert Pro-inflammatory Effects on Macrophages via Passive Cholesterol Depletion and PKC-NF-kappaB/STAT1-IRF1 Signaling. Cell Metab 25, 197-207, doi:10.1016/j.cmet.2016.10.013 (2017).
     
  3. van der Vorst, E. P. C., Theodorou, K., Biessen, E. A. L. & Donners, M. HDL and macrophages: explaining the clinical failures and advancing HDL-based therapeutics in cardiovascular diseases? Expert Rev Cardiovasc Ther 15, 343-344, doi:10.1080/14779072.2017.1313115 (2017).
     
  4. van der Vorst, E. P. C., Theodorou, K., Biessen, E. A. L. & Donners, M. Disease- or Storage-Associated Structural Modifications Are Unlikely to Explain HDL Pro-inflammatory Effects on Macrophages. Cell Metab 26, 4-5, doi:10.1016/j.cmet.2017.05.017 (2017).
     
  5. van der Vorst, E. P. C., Maas, S. L., Ortega-Gomez, A., Hameleers, J. M. M., Bianchini, M., Asare, Y., Soehnlein, O., Doring, Y., Weber, C. & Megens, R. T. A. Functional ex-vivo Imaging of Arterial Cellular Recruitment and Lipid Extravasation. Bio Protoc 7, doi:10.21769/BioProtoc.2344 (2017).
     
  6. van der Vorst, E. P., Zhao, Z., Rami, M., Holdt, L. M., Teupser, D., Steffens, S. & Weber, C. Contrasting effects of myeloid and endothelial ADAM17 on atherosclerosis development. Thromb Haemost 117, 644-646, doi:10.1160/TH16-09-0674 (2017).
     
  7. Theodorou, K., van der Vorst, E. P. C., Gijbels, M. J., Wolfs, I. M. J., Jeurissen, M., Theelen, T. L., Sluimer, J. C., Wijnands, E., Cleutjens, J. P., Li, Y., Jansen, Y., Weber, C., Ludwig, A., Bentzon, J. F., Bartsch, J. W., Biessen, E. A. L. & Donners, M. Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression. Sci Rep 7, 11670, doi:10.1038/s41598-017-10549-x (2017).
     
  8. Rinne, P., Rami, M., Nuutinen, S., Santovito, D., van der Vorst, E. P. C., Guillamat-Prats, R., Lyytikainen, L. P., Raitoharju, E., Oksala, N., Ring, L., Cai, M., Hruby, V. J., Lehtimaki, T., Weber, C. & Steffens, S. Melanocortin 1 Receptor Signaling Regulates Cholesterol Transport in Macrophages. Circulation 136, 83-97, doi:10.1161/CIRCULATIONAHA.116.025889 (2017).
     
  9. Rademakers, T., van der Vorst, E. P., Daissormont, I. T., Otten, J. J., Theodorou, K., Theelen, T. L., Gijbels, M., Anisimov, A., Nurmi, H., Lindeman, J. H., Schober, A., Heeneman, S., Alitalo, K. & Biessen, E. A. Adventitial lymphatic capillary expansion impacts on plaque T cell accumulation in atherosclerosis. Sci Rep 7, 45263, doi:10.1038/srep45263 (2017).
     
  10. Hyafil, F., Pelisek, J., Laitinen, I., Schottelius, M., Mohring, M., Doring, Y., van der Vorst, E. P., Kallmayer, M., Steiger, K., Poschenrieder, A., Notni, J., Fischer, J., Baumgartner, C., Rischpler, C., Nekolla, S. G., Weber, C., Eckstein, H. H., Wester, H. J. & Schwaiger, M. Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer (68)Ga-Pentixafor for PET. J Nucl Med 58, 499-506, doi:10.2967/jnumed.116.179663 (2017).
     
  11. Doring, Y., Noels, H., van der Vorst, E. P. C., Neideck, C., Egea, V., Drechsler, M., Mandl, M., Pawig, L., Jansen, Y., Schroder, K., Bidzhekov, K., Megens, R. T. A., Theelen, W., Klinkhammer, B. M., Boor, P., Schurgers, L., van Gorp, R., Ries, C., Kusters, P. J. H., van der Wal, A., Hackeng, T. M., Gabel, G., Brandes, R. P., Soehnlein, O., Lutgens, E., Vestweber, D., Teupser, D., Holdt, L. M., Rader, D. J., Saleheen, D. & Weber, C. Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence From Mouse and Human Studies. Circulation 136, 388-403, doi:10.1161/CIRCULATIONAHA.117.027646 (2017).